Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 1/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MDM4 | O15151 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 2/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30802567 | 0.91 | KMT2A (0.49) | ITGB3ITGA2BKMT2AMDM4TP53 | |
| SCHEMBL29855073 | 0.91 | KMT2A (0.49) | ITGB3ITGA2BKMT2AMDM4TP53 | |
| SCHEMBL31195699 | 0.91 | KMT2A (0.49) | ITGB3ITGA2BKMT2AMDM4TP53 | |
| SCHEMBL18237209 | 0.91 | KMT2A (0.49) | ITGB3ITGA2BKMT2AMDM4TP53 | |
| SCHEMBL12297754 | 0.91 | KMT2A (0.49) | ITGB3ITGA2BKMT2AMDM4TP53 | |
| SCHEMBL25362440 | 0.91 | ITGB3 (0.45) | MDM2ITGB3ITGA2BKMT2AMDM4 | |
| SCHEMBL25362437 | 0.91 | ITGB3 (0.45) | MDM2ITGB3ITGA2BKMT2AMDM4 | |
| SCHEMBL12568253 | 0.89 | KMT2A (0.46) | MDM2ITGB3ITGA2BKMT2AMDM4 | |
| SCHEMBL32683646 | 0.88 | KMT2A (0.45) | MDM2ITGB3ITGA2BKMT2AMDM4 | |
| SCHEMBL18614206 | 0.88 | KMT2A (0.45) | MDM2ITGB3ITGA2BKMT2AMDM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110223149-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-20110223149-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| WO-2011047215-A1 | IMPROVED PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110223149-A1 | PEPTIDOMIMETIC MACROCYCLES | PREP, ANPEP, DNPEP | MDM2 1052/4885ITGB3 4446/4885ITGA2B 4712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.